menu Search

Cissabex

Cissabex

cisatracurium

Manufacturer:

Able Medical

Distributor:

Universal Medical Industry

Marketer:

Able Medical
Concise Prescribing Info
Contents
Cisatracurium
Indications/Uses
Surgical procedures including cardiac surgery, other procedures & in intensive care. Adjunct to general anesth or sedation in the ICU, to relax skeletal muscles, & to facilitate tracheal intubation & mechanical ventilation.
Click to view Cissabex detailed prescribing information
Dosage/Direction for Use
IV bolus Tracheal intubation Adult 0.15 mg/kg rapidly over 5-10 sec. Maintenance: 0.03 mg/kg. Childn 1 mth to 12 yr 0.15 mg/kg rapidly over 5-10 sec. Maintenance: 0.02 mg/kg. IV infusion Adult & childn 1 mth to 12 yr Maintenance of neuromuscular block Initial infusion rate: 3 mcg/kg/min to restore 89-99% T1 suppression then 1-2 mcg/kg/min to maintain block in this range. Adult ICU patient Initial infusion rate: 3 mcg/kg/min.
Click to view Cissabex detailed prescribing information
Overdosage
View Cissabex overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to cisatracurium, atracurium, or benzene sulfonic acid.
Click to view Cissabex detailed prescribing information
Special Precautions
Hypersensitivity to other neuromuscular blocking agents. Not to be administered into infusion line of blood transfusion. May paralyze resp muscle & other skeletal muscle. Myasthenia gravis & other forms of neuromuscular disease. Severe acid-base &/or serum electrolyte abnormalities; patients w/ burns. Rarely, patients w/ cranial trauma, hypoxia encephalopathy, cerebral edema, viral encephalitis, uremia. Pregnancy & lactation.
Click to view Cissabex detailed prescribing information
Adverse Reactions
Bradycardia; hypotension.
Click to view Cissabex detailed prescribing information
Drug Interactions
Increased effect w/ volatile agents eg, enflurane, isoflurane & halothane; ketamine; other non-depolarizing neuromuscular blocking agents; antibiotics (including aminoglycosides, polymyxins, spectinomycin, tetracyclines, lincomycin & clindamycin); anti-arrhythmics (including propranolol, Ca channel blockers, lidocaine, procainamide & quinidine); diuretics (including furosemide & possibly thiazides, mannitol & acetazolamide); Mg salts; lithium salts; ganglion blocking drugs (trimetaphan, hexamethonium). May aggravate or unmask latent myasthenia gravis or induce myasthenic syndrome w/ antibiotics, β-blockers (propranolol, oxprenolol), anti-arrhythmics (procainamide, quinidine), anti-rheumatics (chloroquine, D-penicillamine), trimetaphan, chlorpromazine, steroids, phenytoin & lithium. Prolonged & complex block w/ suxamethonium. Decreased effect w/ phenytoin or carbamazepine. May shorten duration & diminish magnitude of neuromuscular blockade w/ donepezil.
Click to view Cissabex detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Cissabex detailed prescribing information
Storage
View Cissabex storage conditions for details to ensure optimal shelf-life.
Description
View Cissabex description for details of the chemical structure and excipients (inactive components).
Action
View Cissabex mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Neuromuscular Blocking Agents
ATC Classification
M03AC11 - cisatracurium ; Belongs to the class of other quaternary ammonium-containing agents used as peripherally-acting muscle relaxants.
Presentation/Packing
Form
Cissabex soln for inj 2 mg/mL
Packing/Price
1's
Form
Cissabex soln for inj 5 mg/mL
Packing/Price
1's
Sign up for Free to continue reading
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in